Gilead Sciences Inc. (NASDAQ: GILD) has been touted by many analysts as being a great value stock with serious upside ahead. Gilead remains the top biotech stock that remains well under its highs and potential. On Wednesday, independent research firm Argus issued a research report on the stock. It might seem in line that Gilead was reiterated as Buy. What really matters here is that Argus has a $150 price target.
Read Full Story: How Argus Views Gilead Sciences (NASDAQ: GILD) – 24/7 Wall St.